Steven Hardy, DO
Neurology · Rochester Hills, MINPI 1851652036
Payments from drug & device makers
Across 2,033 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$15K
- Novartis$3K
- UCB, Inc.$2K
- EMD Serono, Inc.$2K
- Bristol Myers Squibb$2K
- Biogen$1K
- plus $18K from 54 others
What the payments were for
- Speaking & faculty fees$11,79327%
- Food & beverage$31,18972%
- Education$1890%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$9,181
- UBRELVY$5,250
- BOTOX$232
- FLOWTRIEVER CATHETER, S$168
- CT THROMBECTOMY SYSTEM KIT$168
- AJOVY$129
- BRIUMVI$125
- VYALEV$124
- AUSTEDO$122
- NOURIANZ$122
- Superion ISS$121
How this compares
$43,171 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 14 | $164,156 |
| Teriflunomide | 55 | $95,175 |
| IngrezzaValbenazine Tosylate | 12 | $93,865 |
| Glatiramer Acetate | 15 | $84,756 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 33 | $82,551 |
| RexultiBrexpiprazole | 30 | $80,137 |
| NuplazidPimavanserin Tartrate | 12 | $61,976 |
| Nurtec OdtRimegepant Sulfate | 27 | $42,887 |
| Emgality PenGalcanezumab-Gnlm | 44 | $36,612 |
| GlatopaGlatiramer Acetate | 12 | $35,606 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 23 | $35,367 |
| AptiomEslicarbazepine Acetate | 21 | $33,769 |
| Aimovig AutoinjectorErenumab-Aooe | 22 | $26,241 |
| Rivastigmine | 95 | $25,414 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $23,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $616 | $93,86512 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $117 | $80,13730 claims |
| Acadia Pharmaceuticals IncNuplazid | $318 | $61,97612 claims |
| PfizerNurtec Odt | $755 | $42,88727 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $268 | $33,76921 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $358 | $23,68614 claims |
| UCB, Inc.Briviact | $1,942 | $18,87414 claims |
| AbbVieUbrelvy | $15,318 | $16,35712 claims |
| Corium, LLCAdlarity | $203 | $5,67613 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $474 | $2,88721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.
Other neurology in Rochester Hills
- Esther YoungRochester Hills$612K
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
- Peter le WittWest Bloomfield$3.2M
- Judith HeidebrinkAnn Arbor$2.2M
- Denise LeungAnn Arbor$2M
- Rany AburashedOwosso$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.